Oral guaifenesin for treatment of filamentary keratitis: A pilot study

Purpose: Pilot study to evaluate the safety and efficacy of oral guaifenesin in reducing the signs and symptoms of filamentary keratitis.Methods: Prospective, uncontrolled open-label pilot study. Twelve patients with non-Sjogren dry eye disease (DED) and secondary filamentary keratitis received treatment with oral guaifenesin 600 mg twice a day (total dose of 1.2 g/day) for 4 weeks. Adverse events, change in the number of corneal filaments, corneal fluorescein staining (CFS; NEI grading system), and symptoms (Ocular Surface Disease Index) were assessed.Results: Before starting oral guaifenesin, all patients were on topical medical therapy for their condition. At baseline, the mean number of filaments was 5.8 +/- 2.9, CFS score 7.3 +/- 3.2, and OSDI score 55.6 +/- 25. After 4 weeks of treatment, the number of filaments was 2.1 +/- 2.2 (p = 0.04 vs. baseline), CFS score 6.5 +/- 3.1 (p = 0.5), and OSDI score 46.1 +/- 30.9 (p = 0.2). One patient discontinued the medication due to gastrointestinal side effects.Conclusions: Oral guaifenesin was safe and generally well tolerated, and demonstrated modest efficacy in reducing the severity of filamentary keratitis. These results should be considered preliminary; however, placebo-controlled investigations would be justified to evaluate the therapeutic efficacy of oral guaifenesin as a mucolytic in treatment of filamentary keratitis.